How and why patients made long Covid by Callard, Felicity & Perego, Elisa
Social Science & Medicine 268 (2021) 113426
Available online 7 October 2020
0277-9536/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Short communication 
How and why patients made Long Covid 
Felicity Callard a,*, Elisa Perego b 
a University of Glasgow School of Geographical and Earth Sciences, University of Glasgow, United Kingdom 
b University College London Institute of Archaeology, UCL, United Kingdom   










A B S T R A C T   
Patients collectively made Long Covid – and cognate term ‘Long-haul Covid’ – in the first months of the 
pandemic. Patients, many with initially ‘mild’ illness, used various kinds of evidence and advocacy to demon-
strate a longer, more complex course of illness than laid out in initial reports from Wuhan. Long Covid has a 
strong claim to be the first illness created through patients finding one another on Twitter: it moved from pa-
tients, through various media, to formal clinical and policy channels in just a few months. This initial mapping of 
Long Covid – by two patients with this illness – focuses on actors in the UK and USA and demonstrates how 
patients marshalled epistemic authority. Patient knowledge needs to be incorporated into how COVID-19 is 
conceptualised, researched, and treated.   
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1. Out of collective suffering 
Long Covid describes a longer, more complex course of illness than 
that emerging from initial, formal reports from Wuhan (The Novel 
Coronavirus Pneumonia Emergency Response Epidemiology Team, 
2020; World Health Organization, 2020a). We document how and why 
patients made Long Covid – and cognate term long-haulers – and why 
this matters for patient activism and pandemic policy-making. While 
most patients initially had ‘mild’ COVID-19 and were not hospitalized, 
many experienced life-threatening symptoms as well as other traumatic 
events, often without healthcare support. Thousands of patients collec-
tively made visible heterogeneous and complexly unfolding symptoms: 
most were not commonly acknowledged within many healthcare and 
policy channels in early pandemic months. 
How scientists engage with knowledge about new diseases affects 
how meaning about a disease accrues, how terminology solidifies, and 
which evidence is prioritized. In a global health crisis, we need contri-
butions made by those with wide ranges of expertise – including, 
crucially, patients. There is a long history of those outside formal clinical 
channels refining or contesting knowledge produced within biomedi-
cine. Mental health survivors have challenged diagnostic categories and 
developed different ways to conceptualize distress and recovery 
(Sweeney et al 2009); HIV/AIDS activists have changed how biomedical 
scientific research is conducted and how drugs are accessed (Robins, 
2004); those with long-term/chronic conditions have created patient 
knowledge and ways of living (Pols, 2013; Kingod, 2018); political or-
ganizations have made clear the biopolitical stakes of health and illness 
(Nelson, 2011). These patient and lay contributions have often been 
ignored or underacknowledged by conventional actors, which has 
intensified patient suffering and societal inequalities. We need to learn 
from these episodes and ensure that patient contributions to the coro-
navirus pandemic are fully acknowledged and incorporated into policy 
making . 
The speed of publication of COVID-19 research means epistemic 
authority rapidly consolidates around particular actors. Crucial leads 
might be lost as background noise – particularly when made by patients, 
whose expertise is less frequently validated. Long Covid now appears in 
peer-reviewed publications (e.g. Altmann and Boyton, 2020; Green-
halgh et al., 2020). Many now writing about it are not aware of whence 
and why it arose. By starting to map Long Covid and related iterations 
(including ‘long-haulers’) which have started to emerge in the English 
language, we aim to ensure their patient origins are evidenced within 
the peer-reviewed literature, as well as emphasize why conventional 
health actors ought to include these contributions within formal scien-
tific practices. 
Long Covid as a patient-made illness carries the potential to change 
how the pandemic unfolds. It has already challenged dominant 
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assumptions about morbidity and disease severity: as science writer Ed 
Yong has argued, Covid ‘[l]ong-haulers … are redefining COVID-19’ 
(Yong, 2020b). There are strong reasons to argue that Long Covid is the 
first illness to be made through patients finding one another on Twitter 
and other social media. Both of us have Long Covid and have contributed 
to making it. Here, we focus on contributions from the UK and USA, 
while emphasizing the need for research on patient contributions from 
other countries – including China, South Korea, and Spain, which were 
affected earlier in the pandemic. 
2. Exploding ‘mild’ covid 
The February WHO-China Report stated ‘the median time from onset 
to clinical recovery for mild cases is approximately 2 weeks and is 3–6 
weeks for patients with severe or critical disease’ (World Health Orga-
nization, 2020a). Early reports focused on severe pneumonia; the ‘mild’ 
was a capacious category including some with pneumonia. Many citi-
zens were told most patients would experience mild illness and rapid 
recovery. The UK’s Chief Medical Officer Chris Whitty stated, in May, 
‘the great majority, probably 80%, will have a mild or moderate disease, 
might be bad enough for them to go to bed for a few days, not bad 
enough for them to have to go to the doctor’ (Refer video at 46 minutes 
in 10 Downing Street, 2020). 
Emollient descriptions of mild illness did not fit with people’s often 
overwhelming experiences. In March, patients started sharing experi-
ences on social media, drawing attention to possible Covid-related 
sequelae (e.g. Pope, 2020). In April, newspapers started publishing 
first-person accounts documenting how challenging recovery from 
COVID-19 could be (e.g. Lowenstein, 2020). Articles often drew on re-
sources developed within patient-founded groups – e.g. Body Politic 
COVID-19 Support Group (https://www.wearebodypolitic.com/co 
vid19, founded by Fiona Lowenstein and Sabrina Bleich), and Face-
book groups (e.g. https://www.facebook.com/groups/longcovid, foun-
ded by Claire Hastie). 
On 5 May, the British Medical Journal (BMJ) published Paul Garner’s 
account of suffering seven weeks through a ‘roller coaster of ill health, 
extreme emotions and utter exhaustion’ (Garner, 2020). Garner, an in-
fectious diseases professor, also appeared in a feature (Harding, 2020b), 
which, by 10 August, had been read over 1 million times (Harding, 
2020a). Garner’s account travelled internationally, gathering a wider 
patient community around what he termed the Covid ‘long tail’. Garner 
reported patients took his account to medical appointments to provide 
evidence of the realness of their symptoms (Colbert et al. n. d.). 
Patient-made evidence in the form of one case study was important 
when no peer-reviewed articles had yet documented long-lasting 
symptoms. Non-hospitalized patients were at that point literally 
beyond the gaze of biomedical research. Patients also challenged ‘mild’: 
Felicity Callard, then seven weeks into Covid, anatomized the ‘mild’, 
emphasizing how little was known about whether mild illness was 
actually mild (Callard, 2020). 
On 11 May, an all-patient team published the first survey of pro-
longed symptoms reporting over 50 (including cognitive impairment/ 
fatigue, chills/sweats, appetite loss), many of them cyclical (Assaf et al., 
2020); the chance of full recovery by day 50 after onset was less than 
20% (see also Lambert, 2020). Other patient-led initiatives included Gez 
Medinger’s videos (https://www.youtube.com/channel/UCln_ 
SCEd4JiGkHIUZd1VlXw), and Kate Porter’s ‘COVID-19 Recovery 
Awareness’ (https://www.c19recoveryawareness.com). 
3. Long-haulers 
In early June, Yong published ‘COVID-19 can last for several months’ 
(Yong, 2020a). Yong’s reputation and the article’s calibre ensured wide 
circulation. (By 19 August, 1 million visitors had read the online version 
[personal communication, Yong, August 19, 2020]). Yong’s article 
featured nine people, described support groups ‘hosting thousands’, and 
noted some called themselves ‘long-haulers’. ‘Long-haulers’ came from 
Amy Watson, patient convener of ‘Long haul Covid fighters’, who 
derived it from a trucker hat she was wearing when getting a test (Porter, 
2020). ‘Long-haulers’ soon moved into general circulation. 
4. Prevalence 
Accounts by patients, support groups, surveys, and digital advocacy 
(e.g. the LongCovidSOS film https://www.longcovidsos.org/film) 
brought vivid case studies to wide audiences, expanded knowledge of 
symptoms, and made demands. But patient-led efforts had to contend 
with epistemological gaps. One concerned prevalence: how common 
were ‘long-haulers’? Patients made strategic use of any incidence data 
available. Notable here was the app-run COVID-19 Symptom Study 
(King’s College London, 2020), the only large study releasing data 
regarding Covid symptoms and duration. In May, we learned that ‘about 
one in 20 Covid patients experience long-term on-off symptoms’ (Har-
ding, 2020b). In June, the study reported ‘one in ten people may still 
have symptoms after three weeks, and some may suffer for months’ 
(COVID-19 Symptom Study App, 2020). Patients made incidence data 
into hashtags (#Covid1in20 – then #Covid1in10). Not until 9 July did 
an article confirm a high incidence of long-term symptoms, showing 
87.4% of hospitalized patients reported at least one symptom 60 days 
after onset (Carfi et al., 2020). 
5. Long Covid 
Long Covid as a term gained consistency in just a few weeks. 
#LongCovid was first used by Elisa Perego, from Lombardy (a very hard- 
hit, early hotspot) on 20 May (Perego, 2020), as a contraction of 
long-term Covid illness, to summarize her experience of disease as 
cyclical, progressive, and multiphasic. She used #LongCovid to inter-
vene ontologically in formulations of COVID-19 in peer-reviewed papers 
– by complicating the ‘biphasic’ disease pathway common in 
peer-reviewed publications (e.g., Lescure et al., 2020), and pointing to 
multiple sequelae. In June, #LongCovid became increasingly prominent 
– complementing other hashtags used by emergent patient collectivities 
(e.g. #apresJ20 in French, #covidpersistente in Spanish; #MitCor-
onaLeben in German; #koronaoire in Finnish; #長期微熱組 in Japanese; 
see also patient websites https://www.apresj20.fr and https://apuakoro 
naan.fi). 
‘Long Covid’ moved from social to print media in late June when a 
newspaper described how doctor Jake Suett had joined a ‘Long Covid’ 
support group (Keay, 2020). This group (https://www.longcovid.org) 
changed its name to ‘Long Covid Support Group’ in response to growing 
use of #LongCovid – having previously added #Covid1in20 to its name 
on 23 May in response to the COVID-19 Symptom Study incidence data 
(personal communication, Claire Hastie, August 19, 2020). 
On 7 July, a BBC interviewer asked Suett about ‘this Long Covid, as 
they call it’ (BBC News 24, 2020a), and the Royal College of General 
Practitioners noted general practice was ‘preparing for an “influx” of 
patients with ‘long Covid’ (Royal College of General Practitioners, 
2020). On 8 July, New Statesman published a piece by a doctor with 
‘#LongCovid’ in the standfirst: the hashtag indicated the term’s emer-
gence through social media (Whitaker, 2020). On 10 July, BMJ pub-
lished a blog by medical doctors with ‘chronic COVID-19 symptoms’ 
titled ‘Patients’ experiences of “longcovid” are missing from the NHS 
narrative’ (Lokugamage et al., 2020). On 14 July, BMJ published the 
clinical feature ‘What do we know about “long Covid”?’ (Mahase, 2020). 
Two days later, UK MP Andrew Gwynne asked in Parliament about 
support for long-term Covid patients, identifying himself as being in 
‘Week 17 of long Covid viral fatigue’ (HC Vol 678, 2020). On 17 July, 
Long Covid reached a journal: an immunological article described ‘the 
chronic aftermath of infection posed by chronic, so-called “long-COVID” 
cases’ (Altmann and Boyton, 2020). 
Then qualifiers such as inverted commas started to disappear. A BBC 
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interview on 20 July noted: ‘We have … been talking more and more 
about long Covid’ (BBC News 24, 2020b). On 26 July, UK MP Layla 
Moran noted the All-Party Parliamentary Group (APPG) on Coronavirus 
was hearing from many suffering from ‘long-lasting effects of corona-
virus, they call it long-Covid’ (Sky News, 2020). Ten days later, when the 
APPG gathered oral evidence, MPs used Long Covid straightforwardly 
(All-Party Parliamentary Group on Coronavirus, 2020). 
By mid-August Long Covid had stabilised into a recognisable ‘sci-
entific object’ (Daston, 2000) – even as its precise contours remain 
subject to debate. On 21 August, the Director-General of the WHO met 
advocates from across the world (Sacks, 2020), after Maria Van Ker-
khove (WHO COVID-19 Technical Lead) contacted the Long Covid SOS 
group in July to discuss advocates’ demands (World Health Organiza-
tion, 2020c). Long Covid and Long-haul Covid were used in communi-
cations within and around the event. On 8 September, Matt Hancock, UK 
Secretary of State for Health and Social Care, used Long Covid when 
speaking to a parliamentary committee (Parliamentlivetv, 2020). 
6. Uptake within formal scientific channels 
Acknowledgement of prolonged Covid illness by the wider scientific 
community often occurred subsequent to patient efforts. In May, Van 
Kerkhove responded to a question about ‘people suffering from symp-
toms for many weeks’ stating, ‘Thus far there is very little evidence to 
suggest there are people who are persistently suffering from COVID-19’ 
(World Health Organization, 2020b). Only on 19 June did Van Kerkove 
note that some ‘mild patients’ were experiencing ‘some lingering effects’ 
(World Health Organization, 2020d). She recognised the need to ‘un-
derstand what recovery looks like’, mentioning ‘our collaborations with 
clinicians and medical professionals’ (World Health Organization, 
2020d). 
Anthony Fauci, the Director of the US’s National Institute of Allergy 
and Infectious Diseases, and an internationally prominent pandemic 
advisor, did not initially invoke clinical networks in relation to long- 
term symptoms but rather – notably – referred to ‘anecdotal’ patient 
data. Here, patient-made material from informal channels was used as 
evidence prior to data being formally available from scientific studies. 
On 9 July, Fauci stated ‘if you look anecdotally, there is no question that 
there are a considerable number of individuals who have a post-viral 
syndrome’. Fauci mentioned as evidence ‘chat groups that you just 
click on and see people who recovered that really do not get back to 
normal’ (Fox, 2020). In late July, Avindra Nath and Jeanne Billioux (US 
National Institutes of Health) wrote on ‘long-haul Covid’ (Nath and B 
Jeanne Billioux, 2020), picking out autonomic symptoms. Which evi-
dence they drew on for their typology was unclear; a broader range of 
symptoms had already been reported in patient-led surveys. 
In July, peer-reviewed studies started reporting sequelae (cardio-
logical, neurological) even in ‘mild’ COVID-19 (Paterson et al., 2020; 
Puntmann et al., 2020; Tenforde, 2020). These papers circulated widely 
online under the Long Covid hashtag. Patients continued to initiate 
medical discussions on Twitter – speculating about aetiologies and 
treatments. By late July, scientists on Twitter used ‘Long Covid’ them-
selves (e.g. on 28 July, Eric Topol launched a challenge to ‘demystify … 
what accounts for #LongCovid’ (Topol, 2020)). Patients were not al-
ways explicitly included as addressees in such discussions. 
7. An unstable term 
The aetiology of Long Covid is currently under scrutiny and may be 
multiple (Perego et al., 2020). Definitions of COVID-19 itself remain 
unstable: the pathology has been defined as a respiratory, cardiovas-
cular, endothelial, or systemic condition (Lescure et al., 2020; Marini 
and Gattinoni, 2020). Whether COVID-19 will, for some, survive viral 
persistence and develop into a disease-specific, chronic or permanent 
condition, and/or whether SARS-COV-2 infection generates a new 
autoimmune disease remains unknown (Topol et al., 2020). Many 
patients, through use of Long Covid, wish to keep aetiological possibil-
ities open while much remains unclear. 
Nonetheless, Long Covid has been under pressure to conform to or be 
subsumed within other terms. Some already exist (e.g. post-viral fatigue 
syndrome, ME/CFS). Others are COVID-19 specific (e.g. ‘post-Covid 
syndrome’ (BBC, 2020)). Some in the ME/CFS community have sug-
gested some Long Covid cases might morph into ME/CFS (Shepherd, 
2020), and there are already lively exchanges both over the relationship 
between Long Covid and ME/CFS, over forms of solidarity between two 
patient communities experiencing ‘chronic viral-induced illness’, and 
diagnostic terminology for persistent symptoms. It is crucial, we argue, 
that Long Covid patients with different disease experiences and path-
ways are included in deliberations over terminologies used for long-term 
symptoms/illness: the history of medicine demonstrates much is at stake 
in terms of how diseases are modelled and understood (Dumit, 2006). 
8. Ethics and exploitation 
Patients continue to experience epistemic injustice (Fricker, 2011) – 
their long-term symptoms misunderstood, or reduced to anxiety (Yong, 
2020b); patients of colour and those with disabilities are particularly at 
risk. Many struggle to receive care, particularly if they were not tested. 
The ownership and interpretation of patient-held materials pose ethical 
and practical challenges. Huge datasets of symptoms and potential 
therapeutics are held in informal patient archives, comprising signifi-
cant evidence from first cohorts. Comparably rich information might not 
be accrued by research studies fast enough to help emerging Covid 
hotspots and direct policy. Urgent attention needs to be given to 
ensuring ethical means of engaging with these data: it is essential these 
acknowledge the forms of solidarity that underpinned their emergence 
while learning from previous episodes of patient data exploitation 
(Prainsack, 2017). 
9. Conclusion 
Long Covid challenges common assumptions that were in place in the 
early pandemic and which often persisted despite patient testimony. In 
the making of Long Covid, conventional hierarchies of evidence, and 
normative routes for scientific dissemination were frequently disrupted. 
A patient-led survey released on a collective’s website; the self- 
appellation of a community after a trucker hat; a single case study 
authored by a patient, and taken by others to clinical appointments; the 
circulation of a hashtag first used by a patient to refine the model of 
COVID-19 in published articles. Through such acts Long Covid solidi-
fied, moving from patients to multiple new actors – with some con-
ventional scientific actors arriving on the scene after patients. We note 
the speed of consolidation: Long Covid and Long-haul Covid moved from 
patients to meetings with the WHO in just a few months. Will Long Covid 
persist as a term, or will this ‘scientific object’, which, by late August 
2020, achieved solidity, break up into other classifications (Callard, 
2020)? 
In HIV/AIDS science, ‘knowledge emerge[d] out of credibility 
struggles’ involving activists who challenged divisions between scientist 
‘insiders’ and lay ‘outsiders’ (Epstein, 1996). As with AIDS, Covid pa-
tients have used various tactics to claim epistemic authority – often by 
marshalling authority relating to professional expertise (e.g. Medinger is 
a film director, Lowenstein a writer). It was frequently patients with 
professionally validated forms of authority who were more able to ac-
cess formal routes, which helped stabilize patient-made terms (e.g. 
medical doctors [e.g. Suett on BBC], academics in medicine/health [e.g. 
Garner in BMJ blog], parliamentarians [e.g. Gwynne]). Many clinicians 
and researchers at the forefront of Long Covid research and advocacy (e. 
g. Alwan, 2020a, 2020b; Lokugamage et al., 2020) have had Covid. 
Others carved out authority by dint of being patients (e.g. Hastie pre-
sented at APPG). Those who introduced the terms ‘long-haulers’ and 
‘Long Covid’, as well as many of those providing labour in COVID-19 
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support and advocacy, are women. How authority has been recognised 
intersects in overdetermined ways with gender, ethnicity, class, and 
disability. Discrimination – including racism, sexism, ableism – helps 
explain why patients from marginalized/minoritized communities, 
many of whom are central to making Long Covid, have been denied 
platforms, and sometimes have decided not to place themselves in the 
spotlight to discuss a disease that compounds discrimination. Some with 
professional power, e.g. Yong, amplified patient contributions. Others 
have not. 
Long Covid has a strong claim to be considered the first illness to be 
collectively made by patients finding one another through Twitter and 
other social media. This phenomenon opens multiple questions: How 
does Long Covid shift assumptions about the role of media in the pro-
duction of science? Are Long Covid patients developing different ways of 
authorising their knowledge claims from those used elsewhere? How 
might the specific characteristics of COVID-19 and Long Covid (partic-
ularly the apparent heterogeneity of illness pathways and the current 
difficulty in knowing who will develop protracted illness/disability) 
matter in conceptualising ‘acute’ and ‘chronic’ illnesses (see Manderson 
and Wahlberg, 2020)? Do responses to Long Covid patients from con-
ventional scientists differ from those experienced by others with pro-
tracted illness (e.g. the tendency to describe ME/CFS advocacy as 
‘militant’ (Blease and Geraghty, 2018), and if so why? 
Crucially, researchers’ accounts of patient activism during the 
pandemic need to learn from other epidemics: privileging white men in 
narratives about AIDS occluded contributions by and impacts on those in 
the Global South (Cheng et al., 2020). Our short communication on Long 
Covid is one small piece of a much bigger story. We have explained how 
and why patients in, or with links to, certain English-speaking countries 
collectively produced knowledge, circulated it through multiple media, 
and broadened what counts as evidence. We end by calling for the work 
of more actors to be documented, and for patients’ ongoing contribu-
tions to be recognised and used to combat the suffering of multitudes. 
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